Skip to Content

Seroquel XR Approval History

FDA Approved: Yes (First approved May 17, 2007)
Brand name: Seroquel XR
Generic name: quetiapine
Dosage form: Tablets
Company: AstraZeneca
Treatment for: Schizophrenia, Bipolar Disorder, Depression, Major Depressive Disorder

Seroquel XR (quetiapine) is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia, bipolar disorder and as an adjunctive treatment to antidepressants in adults with Major Depressive Disorder.

Development History and FDA Approval Process for Seroquel XR

DateArticle
Dec  4, 2009Approval FDA Approves Seroquel XR For Add-On Treatment of Major Depressive Disorder
Oct 10, 2008Approval FDA Approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US
Nov 16, 2007Approval Seroquel XR Receives Approval From FDA for Maintenance Treatment ofSchizophrenia
May 18, 2007Approval FDA Approves Astrazeneca's Once-Daily Seroquel XR Extended-ReleaseTablets for the Treatment of Schizophrenia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide